Predictors of shortages of opioid analgesics in the US: Are the characteristics of the drug company the missing puzzle piece?

• Published in: PloS one 2021-03, Vol.16 (3), p.e0249274-e0249274
• Main Authors: Rodriguez-Monguio, Rosa, Naveed, Mahim, Seoane-Vazquez, Enrique
• Format: Article
• Language: English
• Subjects: Analgesics; Drug dosages; Economic aspects; Economics; Editing; Estimates; FDA approval; Generalized linear models; Health care expenditures; Health policy; Health risks; Manufacturers; Manufacturing; Medicine and Health Sciences; Methodology; Mitigation; Narcotics; Opioids; Performance evaluation; Pharmaceutical industry; Pharmacy; Physical Sciences; Regression analysis; Regression models; Research and Analysis Methods; Reviews; Schedules; Shortages; Social aspects; Social Sciences; Supply and demand
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0249274

Shortages of opioid analgesics are increasingly common, interfere with patient care and increase healthcare cost. This study characterized the incidence of shortages of opioid analgesics in the period 2015-2019 and evaluated potential predictors to forecast the risk of shortages. This was an observational retrospective study using the US Food and Drug Administration (FDA) drug shortages data. All FDA approved opioids were included in the study. Opioid analgesics were identified using the FDA National Drug Codes (NDC) and classified according to the Drug Enforcement Administration (DEA) schedule. We conducted Least Absolute Shrinkage and Selection Operator logistic regression analysis to assess direction of the association between risk of shortage and potential predictors. We used multivariable penalized logistic regression analysis to model predictors of shortages. We split the dataset into training and validation sets to evaluate the performance of the model. The FDA approved 8,207 unique NDCs for opioid analgesics; 3,017 (36.8%) were in the market as of April 30, 2019 and 91(3.0%) of them were listed as in shortage by the FDA. All NDCs in shortage were schedule II opioids; 86 (94.5%) were injectable and 84 (92.3%) generics. There were 418 companies with at least one opioid NDC listed by the FDA. Three companies accounted for more than 4 in 5 of the schedule II active injectable opioids. For each unit increase in the number of prior instances of shortages of a company, the likelihood of an NDC shortage for that company increased by 3.4%. For each unit increase in number of NDCs marketed by a company, the odds of an NDC shortage for that company decreased by 1%. In the period 2015-2019, shortages of opioid analgesics disproportionally impacted schedule II and injectable opioids. The risk of shortage of opioid analgesics significantly increased with the incidence of previous instances of shortages of a manufacturing company and decreased with the number of NDCs marketed by a company. The characteristics of the manufacturing company, rather than the number of companies, might be the missing piece to the complex puzzle of drug shortages in the US.